Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baofukang suppository for HPV16/18-positive p16-positive CIN II
ChiCTR2100043958Phase 2Not yet recruiting
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Feb 2021
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of baofukang shuan in human papillomavirus infection and cervical intraepithelial neoplasia (CIN) (4 arms), sponsored by Beijing Tsinghua Changgung Hospital. Primary endpoints: Reversal rate of HSIL (p16-positive CIN II) at the 7th menstrual cycle and Negative conversion rate of cervical HR-HPV16/18 at the 7th menstrual cycle. Planned start Feb 2021; status: not yet recruiting.
02
Drugs
baofukang shuan
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on ChiCTR2100043958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043958.